AbbVie Inc. (ABBV)
After hours:
| Previous close | 167.29 |
| Open | 167.09 |
| Bid | 159.65 x 800 |
| Ask | 159.76 x 800 |
| Day's range | 157.65 - 167.46 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,630,903 |
| Market cap | 282.631B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 58.47 |
| EPS (TTM) | 2.73 |
| Earnings date | 25 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | 6.20 (3.71%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | 184.70 |
- Yahoo Finance Video
Abbvie stock falls amid growing biosimilar competition
Pharmaceutical giant AbbVie Inc. (ABBV) shares came under pressure as the market closed on Friday, following the disappointing first quarter sales performance of the company's arthritis drug, Humira. The company forecast that Humira's sales could slow further in the face of heightened competition. Yahoo Finance's health reporter Anjalee Khemlani breaks down the details, providing insight into the rise of biosimilars in the market. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith
Investor's Business DailyAbbVie Is 'Firing On All Cylinders,' But Its Stock Doesn't Show That
AbbVie is "firing on all cylinders," an analyst said Friday after the firm beat first-quarter estimates. But AbbVie stock fell.
ZacksAbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
